Intervention

Voglibose

ClinicalTrials.gov intervention label

Clinical trials8

Recruiting0

Common conditions5

Lead sponsors shown5

Clinical trials

8 shown

Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 DiabetesNCT02049814 · 2014-05-09

Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes MellitusNCT02097342 · 2013-12-01

Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 DiabetesNCT01309698 · 2011-02-01

MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)NCT00837577 · 2009-02-05

Glufast On Insulin Glargine Trial in Type 2 DMNCT00663884 · 2008-02-01

Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in JapanNCT01263496 · 2007-05-01

Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in JapanNCT01263483 · 2007-01-01

Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in JapanNCT01263470 · 2007-01-01

Common conditions

Type 2 Diabetes Mellitus4 Diabetes Mellitus, Type 22 Diabetes Mellitus, Non-Insulin-Dependent1 Insulin Sensitivity/Resistance1 Type 2 Diabetes1

Leading sponsors

Takeda4 JW Pharmaceutical1 Merck Sharp & Dohme LLC1 Novartis Pharmaceuticals1 Post Graduate Institute of Medical Education and Research, Chandigarh1

Trial status mix

COMPLETED7

UNKNOWN1

Phase mix

PHASE44

PHASE23

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.